Leslie F. Varon
Leslie F. Varon's purchase track record
Leslie F. Varon has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2025 | XRAY | $100K | +18.6% | -5.5% | +12.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Lam Research Q1 Earnings Preview Amid Chip Equipment Sector Slump. Lam Research is preparing for its Q1 earnings report while the broader chip equipment sector faces pressure from AI spending concerns. The stock has recently touched its 200-day moving average, a technical level that often signals a potential trend change. Investors are watching to see if the company's strong return on invested capital can offset the current market volatility.
Transaction History
| HLNE | ▲ Buy | Grant | 977 | $0 | 9/16/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 22,822 | $0 | 6/3/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 198 | $0 | 1/9/2026 | View on chart |
| XRAY | ▲ Buy | Open Market | 9,337 | $100K | 11/24/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 179 | $0 | 10/10/2025 | View on chart |
| HLNE | ▲ Buy | Grant | 666 | $0 | 9/16/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 139 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 13,880 | $0 | 5/22/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 87 | $0 | 4/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 68 | $0 | 1/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 48 | $0 | 10/11/2024 | View on chart |
| HLNE | ▲ Buy | Grant | 669 | $0 | 9/16/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 51 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 7,994 | $0 | 5/23/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 36 | $0 | 4/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 31 | $0 | 1/12/2024 | View on chart |
| LRCX | ▲ Buy | Grant | 369 | $0 | 11/10/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 59 | $0 | 10/13/2023 | View on chart |
| HLNE | ▲ Buy | Grant | 1,474 | — | 9/16/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 50 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 5,419 | $0 | 5/25/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 31 | $0 | 4/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 34 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 6,382 | $0 | 11/15/2022 | View on chart |
| LRCX | ▲ Buy | Grant | 563 | $0 | 11/11/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 11 | $0 | 10/14/2022 | View on chart |
| HLNE | ▲ Buy | Grant | 1,256 | — | 9/16/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 8 | $0 | 7/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 14 | $0 | 4/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 11 | $0 | 1/14/2022 | View on chart |
| LRCX | ▲ Buy | Grant | 377 | $0 | 11/12/2021 | View on chart |
| XRAY | ▲ Buy | Grant | 10 | $591 | 10/8/2021 | View on chart |
| HLNE | ▲ Buy | Grant | 1,022 | — | 9/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Wells Fargo initiates coverage on Hamilton Lane with Overweight rating
Wells Fargo has started covering Hamilton Lane, assigning an Overweight rating and a price target of $103. This new analyst view comes as the company prepares to report second-quarter results in November. Additionally, attention is turning to the planned 2027 retirement of a key executive, which may influence long-term expectations for the firm.
Wells Fargo initiates coverage on Hamilton Lane with Overweight rating. Wells Fargo has started covering Hamilton Lane, assigning an Overweight rating and a price target of $103. This new analyst view comes as the company prepares to report second-quarter results in November. Additionally, attention is turning to the planned 2027 retirement of a key executive, which may influence long-term expectations for the firm.